Adenosine is an evolutionary ancient metabolic regulator linking energy state to physiologic
processes, including immunomodulation and cell proliferation. Tumors create an adenosine …

Ischaemic heart disease and the heart failure that often results, remain the leading causes of
death and disability in Europe and worldwide. As such, in order to prevent heart failure and …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …

Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

Adenosine, a nucleoside derived primarily from the extracellular hydrolysis of adenine
nucleotides, is a potent regulator of inflammation. Adenosine mediates its effects on …

Background: Few data on the relative efficacy and safety of new P2Y 12 inhibitors such as
prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …